EVOGENE LTD (NASDAQ: EVGN)

1. Introduction to the Company

EVOGENE LTD (Korean name: 에보진) is a computational biology company headquartered in Rehovot, Israel. Founded in 2002, the company develops life-science products using its proprietary Computational Predictive Biology (CPB) platform, which incorporates biological understanding with big data and artificial intelligence (AI). Its solutions encompass three core areas:

• Microbe-based products
• Small molecule-based products
• Genetic element-based products

As of June 10, 2025, EVOGENE shares traded at USD 2.16, reflecting a 91.15% increase on a volume of 20,604,315 shares.

2. Corporate Structure and Personnel

Headquarters: Rehovot, Israel
Public Listings:

• NASDAQ: EVGN
• Tel Aviv Stock Exchange: EVGN.TA

Employee Count: 51–200

Subsidiaries and Focus Areas:

Subsidiary	Focus
Biomica Ltd.	Human microbiome-based therapeutics
Lavie Bio Ltd.	Ag-biologicals (assets sale in Q2 2025)
AgPlenus Ltd.	Agricultural chemicals
Casterra Ltd.	Castor oil production for biofuels

Key Technological Engines:

• MicroBoost AI (microbes)
• ChemPass AI (small molecules)
• GeneRator AI (genetic elements)

3. Recent Developments and News

• June 10, 2025

  • EVOGENE announced the completion of its first-in-class generative AI foundation model for novel small molecule design, developed in collaboration with Google Cloud.

• June 5, 2025

  • SEC Form 6-K disclosed leadership changes at Biomica Ltd.: Dr. Elran Haber resigned for health reasons, and Ofer Haviv was appointed CEO effective June 8, 2025. Biomica will reduce internal R&D activities and headcount while maintaining its Phase I clinical trial for drug candidate BMC128.

• May 21, 2025

  • EVOGENE filed a Form 6-K reporting Q1 2025 financial results (period ended March 31, 2025) and hosted a conference call with investors to discuss performance metrics.

• April 21, 2025

  • EVOGENE announced the sale of most of Lavie Bio Ltd.’s operations to Dead Sea Works Ltd. (ICL Group) for USD 15.25 million, along with the acquisition of the MicroBoost AI tech engine for USD 3.5 million. Completion was expected in Q2 2025, subject to customary closing conditions.

4. Financial and Strategic Aspects

Trading and Valuation (as of June 10, 2025):

• Share Price: USD 2.16 (day’s range: 1.85–2.42)
• 52-Week Range: 0.95–7.20
• Intraday Market Cap: ~USD 12.55 million
• Beta (5Y): 1.37

Key Metrics (TTM):

• Revenue: USD 6.76 million
• Net Loss: USD 15.21 million
• EPS: –2.51
• Profit Margin: –224.82%
• Total Cash (MRQ): USD 9.85 million
• Debt/Equity (MRQ): 20.91%
• Free Cash Flow: –USD 3.16 million

Strategic Initiatives:

• AI Platform Commercialization: Utilizing generative AI to design patentable molecules, with plans to license technology engines such as ChemPass AI and MicroBoost AI.
• Capital-Efficiency Shift: The April 21, 2025, asset sale indicates a strategic focus on a leaner cost structure and high-value assets.
• Partnership Model: Ongoing collaborations with industry players (BASF, Bayer, Corteva, Google Cloud) and academic institutions for co-development and sharing of development costs.

5. Market Position and Industry Context

• Competitive Landscape: EVOGENE operates at the intersection of biotechnology and AI, focusing on drug discovery, agricultural biotechnology, and industrial applications.
• Collaborations: Partnerships with significant agribusiness and pharmaceutical firms enhance the relevance of its CPB platform.
• Regulatory and Geopolitical Factors: operations may be impacted by international regulatory approvals for biotech products and regional stability in Israel.
• Sector Trends: The integration of AI in life-science R&D is increasing, driven by the need for faster lead identification and reduced development costs.

6. tl;dr

• June 10, 2025: Announced the completion of a generative AI model for small molecules in collaboration with Google Cloud.
• June 8, 2025: Ofer Haviv became CEO of Biomica Ltd. following Dr. Elran Haber’s resignation.
• Q2 2025: Expected closing of Lavie Bio Ltd. asset sale to Dead Sea Works (ICL Group) for USD 15.25 million plus USD 3.5 million for the MicroBoost AI engine.
• Q1 2025 Results (period ended March 31): Discussed during a May 21 investor call; detailed metrics in SEC Form 6-K.
• Next earnings window: August 20–25, 2025.